EDITORIAL ARTICLE
Gout – new diagnostic and therapeutic options
Online publication date: 2013-03-05
Reumatologia 2013;51(1):1-8
KEYWORDS
ABSTRACT
Gout is a disorder characterized by deposition of monosodium urate crystals in different tissues within the body and especially the joints. Inflammatory arthritis is a typical manifestation of gout. New evidence from recent research has become available for both the diagnosis and treatment of patients with gout. The basic goal of treatment is lowering of the monosodium urate level (urate lowering therapy – ULT). Despite high frequency of the disease and the availability of effective drugs, only a minority of gout patients receive appropriate treatment. This paper is aimed at analyzing the possibility of comprehensive effective treatment of gout based on new data regarding the pathogenesis of gouty arthritis according to the recent recommendations.
REFERENCES (23)
2.
Martinon F, Glimcher LH. Gout: new insights into an old disease. J Clin Invest 2006; 116: 2073-2075.
3.
Liote F, Hang-Korng E. Recent developments in crystal – induced inflammation pathogenesis and management Curr Rheumatol Rep 2006; 18: 249-255.
4.
Dalbeth N. Gout in 2010: progress and controversies in treatment. Nat Rev Rheumatol 2011; 7: 77-78.
5.
So A. Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008; 10: R221.
6.
Ellman MH, Becker MA. Crystal-induced arthropathies: recent investigative advances. Curr Opin Rheumatol 2006; 18: 249-255.
7.
Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010; 6: 30-38.
8.
Majdan M. Zapalenie stawów wywołane przez kryształy. W: Reumatologia, red M. Puszczewicz, Wielka Interna, Medical Tribune Polska, 2010; 317-328.
10.
Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in managed care population. J Rheumatol 2004; 31: 1582-1587.
11.
Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63: 3136- 3141.
12.
Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012; 64: 1431-1446. .
13.
Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012; 64: 1447-1461. .
14.
Zhang W, Doherty M, Pascual E, et al. Eular evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301-1311.
15.
Zhang W, Doherty M, Bardin T, et al. Eular evidence based recommendations for gout. Part II: Management. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324.
16.
Sundy JS. Progress in the pharmacotherapy of gout. Curr Opin Rheumatol 2010; 22: 188-193.
17.
Schumacher HR, Evans RR, Saag KG, et al. Rilonacept (Interleu-kin-1 Trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blinded, placebo-controlled confirmatory efficacy study. Arthritis Care Res 2012; 64: 1462-1470.
18.
Choi KCh, Burns LC, Shojania K. Dual energy CT in gout: a prospective validation study. Ann Rheum Dis 2012; 71: 1466-1471.
19.
Gaffo AL, Schumacher HR, Saag KG, et al. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum 2012; 64: 1508-1517.
20.
Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout. The CONFIRMS trial. Arthritis Res 2010; 12: R63.
21.
Chohan S, Becker MA, Mc Donald PA, et al. Women with gout: efficacy and safety of urate- lowering with febuxostat and allopurinol. Arthritis Care Res 2012; 64: 256-261.
22.
Becker MA, Baraf HSB, Yood RA. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis 2012 online (http://dx.doi.org/10.1136/annr...).
23.
Gigiel E, Hrycaj P. Nowe leki w leczeniu dny moczanowej. Reumatologia 2009; 47: 344-347.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
